Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 602,285 shares, an increase of 289.0% from the June 15th total of 154,817 shares. Currently, 12.9% of the company’s stock are short sold. Based on an average daily trading volume, of 18,970,380 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology at the end of the most recent reporting period. Institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Trading Down 3.1%

NASDAQ CELZ traded down $0.03 during trading hours on Friday, reaching $0.91. 348,255 shares of the company traded hands, compared to its average volume of 10,086,134. The stock has a market capitalization of $4.32 million, a PE ratio of -0.43 and a beta of 1.89. Creative Medical Technology has a 12 month low of $0.79 and a 12 month high of $6.25. The company has a 50 day moving average of $1.97 and a two-hundred day moving average of $2.00.

Creative Medical Technology (NASDAQ:CELZ) last released its earnings results on Friday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.01. On average, equities research analysts anticipate that Creative Medical Technology will post -1.14 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Friday, May 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Creative Medical Technology has an average rating of “Reduce”.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.